Gyre Therapeutics (Gyre Therapeutics) Revenue : $ Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Revenue?

Gyre Therapeutics's revenue for the six months ended in Dec. 2023 was $113.5 Mil. Gyre Therapeutics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Dec. 2023. Gyre Therapeutics's Revenue per Share for the six months ended in Dec. 2023 was $1.72. Gyre Therapeutics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023.

During the past 12 months, the average Revenue per Share Growth Rate of Gyre Therapeutics was 29.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Gyre Therapeutics Revenue Historical Data

The historical data trend for Gyre Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Revenue Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Revenue

89.59

102.29

113.45

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
Revenue	89.59	102.29	113.45

Competitive Comparison of Gyre Therapeutics's Revenue

For the Biotechnology subindustry, Gyre Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Revenue falls into.

Gyre Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Gyre Therapeutics (NAS:GYRE) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Gyre Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023